45 / 210
Ponencias
45
7. Geng Y, Verhamme IM, Smith SB, Sun M-F, Matafonov A, Cheng
Q, et al. The dimeric structure of factor XI and zymogen activation.
Blood 2013;121:3962-9.
8. Choi SH, Smith SA, Morrissey JH. Polyphosphate is a cofactor for
the activation of factor XI by thrombin. Blood 2011;118:6963-70.
9. Zhu S, Travers RJ, Morrissey JH, Diamond SL. FXIa and platelet
polyphosphate as therapeutic targets during human blood clotting on
collagen/tissue factor surfaces under flow. Blood 2015;126:1494-502.
10. Seligsohn U. Factor XI deficiency in humans. J Thromb Haemost
2009;7 (Suppl 1): 84-7.
11. Pike GN, Cumming AM, Hay CRM, Bolton-Maggs PHB, Burthem
J. Sample conditions determine the ability of thrombin generation
parameters to identify bleeding phenotype in FXI deficiency. Blood
2015;126:397-405.
12. Maroney SA, Cooley BC, Ferrel JP, Bonesho CE, Nielsen L V,
Johansen PB, et al. Absence of hematopoietic tissue factor pathway
inhibitor mitigates bleeding in mice with hemophilia. Proc Natl Acad
Sci USA 2012;109:3927-31.
13. Zucker M, Seligsohn U, Salomon O, WolbergAS. Abnormal plasma
clot structure and stability distinguish bleeding risk in patients with
severe factor XI deficiency. J Thromb Haemost 2014;12:1121-30.
14. RevenkoAS, Gao D, Crosby JR, Bhattacharjee G, Zhao C, May C, et
al. Selective depletion of plasma prekallikrein or coagulation factor
XII inhibits thrombosis in mice without increased risk of bleeding.
Blood 2011;18:5302-11.
15. Wang X, Cheng Q, Xu L, Feuerstein GZ, Hsu M-Y, Smith PL, et al.
Effects of factor IX or factor XI deficiency on ferric chloride-induced
carotid artery occlusion in mice. J Thromb Haemost 2005;3:695-702.
16. Salomon O, Steinberg DM, Zucker M, Varon D, Zivelin A,
Seligsohn U. Patients with severe factor XI deficiency have a
reduced incidence of deep-vein thrombosis. Thromb Haemost
2011;105:269-73.
17. Meijers JC, Tekelenburg WL, Bouma BN, Bertina RM, Rosendaal
FR. High levels of coagulation factor XI as a risk factor for venous
thrombosis. N Engl J Med 2000;342:696-701.
18. Büller HR, Bethune C, Bhanot S, Gailani D, Monia BP, et al. Factor
XI Antisense Oligonucleotide for Prevention of Venous Thrombosis.
N Engl J Med 2014;372:232-40.
19. Von Brühl ML, Stark K, Steinhart A, Chandraratne S, Konrad I,
Lorenz M, et al. Monocytes, neutrophils, and platelets cooperate
to initiate and propagate venous thrombosis in mice in vivo. J Exp
Med 2012;209:819-35.
20. Cheng Q, Tucker EI, Pine MS, Sisler I, Matafonov A, Sun M-F, et
al. A role for factor XIIa-mediated factor XI activation in thrombus
formation in vivo. Blood 2010 [cited 2012 Oct 19];116:3981-9.
21. Gruber A, Hanson SR. Factor XI-dependence of surface- and
tissue factor-initiated thrombus propagation in primates. Blood
2003;102:953-5.
22. Wong PC, Quan ML, Watson CA, Crain EJ, Harpel MR, Rendina
AR, et al. In vitro, antithrombotic and bleeding time studies of BMS-
654457, a small-molecule, reversible and direct inhibitor of factor
XIa. J Thromb Thrombolysis 2015;40:416-23.
23. Karuturi R, Al-Horani RA, Mehta SC, Gailani D, Desai UR. Dis-
covery of allosteric modulators of factor XIa by targeting hydro-
phobic domains adjacent to its heparin-binding site. J Med Chem
2013;56:2415-28.